Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management of this growing population, categorized as heart failure with improved...

Descripción completa

Detalles Bibliográficos
Autores principales: Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800271/
https://www.ncbi.nlm.nih.gov/pubmed/36522606
http://dx.doi.org/10.1038/s41591-022-02102-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800271/
https://www.ncbi.nlm.nih.gov/pubmed/36522606
http://dx.doi.org/10.1038/s41591-022-02102-9

Ejemplares similares